Skip to main content

Table 2 Association of clinicopathological parameters and HDAC-1, −2, −4 and −6 expression with patients’ survival: Univariate analysis

From: Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

Clinicopathological variables   Median overall survival (95 % CI) p-value
Age <66.77 yrs 8.0 (6.7–9.3) 0.3876
≥66.77 yrs 8.0 (7.2–8.8)  
Gender Male 8.0 (7.3–8.7) 0.1343
Female 7.0 (6.2–7.8)  
Histopathological grade I + II 8.0 (7.2–8.8) 0.8963
III 7.0 (5.8–8.2)  
pT T1 + T2 11.0 (5.3–16.7) <0.0001
T3 + T4 7.0 (6.2–7.8)  
pN N0 11.0 (9.8–12.2) <0.0001
N1 7.0 (6.5–7.5)  
pM M0 8.0 (7.2–8.8) <0.0001
M1 4.0 (3.9–5.1)  
pStage I + II 8.0 (6.9–9.2) <0.0001
III + IV 5.0 (3.9–6.0)  
Ki-67 protein statement ≤ median 8.0 (7.1–8.7) 0.8581
> median 7.0 (5.9–8.1)  
HDAC-1 expression Low 7.0 (6.3–7.7) 0.0022
High 10.0 (8.8–11.2)  
HDAC-2 expression Low 7.0 (5.9–8.1) 0.0634
High 8.0 (6.1–9.9)  
HDAC-4 expression Low 8.0 (7.1–8.9) 0.5061
High 8.0 (6.7–9.3)  
HDAC-6 expression Low 7.0 (6.2–7.8) 0.0113
High 10.0 (7.6–12.4)